Stimulation	O
of	O
a	O
human	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
with	O
anti-CD3	B-protein
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
induces	O
NF-kappa	B-protein
B	I-protein
translocation	O
but	O
not	O
human	O
immunodeficiency	O
virus	O
1	O
enhancer-dependent	O
transcription	O
.	O

The	O
expression	O
of	O
transiently	O
transfected	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
or	O
its	O
enhancer	B-DNA
sequence	I-DNA
and	O
the	O
translocation	O
of	O
the	O
HIV	B-protein
enhancer-binding	I-protein
protein	I-protein
NF-kappa	B-protein
B	I-protein
were	O
analyzed	O
in	O
two	O
human	O
T-cell	B-cell_line
clones	I-cell_line
stimulated	O
through	O
their	O
T-cell	B-protein
receptor	I-protein
complex	I-protein
or	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

We	O
found	O
a	O
dissociation	O
of	O
NF-kappa	B-protein
B	I-protein
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	B-DNA
LTR	I-DNA
or	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O

Interleukin	B-protein
2	I-protein
induced	O
proliferation	O
but	O
not	O
NF-kappa	B-protein
B	I-protein
translocation	O
or	O
LTR	B-DNA
transactivation	O
.	O

Phorbol	O
ester	O
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	B-DNA
LTR	I-DNA
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
antibody	O
to	O
CD3	B-protein
did	O
not	O
.	O

The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF-kappa	B-protein
B	I-protein
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band-shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O

Our	O
finding	O
that	O
induction	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
or	O
antibody	B-protein
to	I-protein
CD3	I-protein
is	O
not	O
sufficient	O
to	O
induce	O
HIV	B-DNA
enhancer	I-DNA
-dependent	O
transcription	O
in	O
cloned	B-cell_line
T	I-cell_line
cells	I-cell_line
contrasts	O
with	O
results	O
obtained	O
in	O
most	O
lymphoblastoid	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
and	O
indicates	O
that	O
normal	O
T	B-cell_type
lymphocytes	I-cell_type
differ	O
from	O
tumoral	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
terms	O
of	O
requirements	O
for	O
HIV	B-DNA
LTR	I-DNA
activation	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T-cell	O
activation	O
,	O
in	O
addition	O
to	O
NF-kappa	B-protein
B	I-protein
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
with	O
the	O
HIV	B-DNA
enhancer	I-DNA
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

87	NULL
,	NULL
pp	NULL
.	NULL

7861-7865	NULL
,	NULL
October	NULL
1990	NULL
Immunology	NULL
Stimulation	NULL
of	NULL
a	NULL
human	NULL
T-cell	NULL
clone	NULL
with	NULL
anti-CD3	NULL
or	NULL
tumor	NULL
necrosis	NULL
factor	NULL
induces	NULL
NF-B	NULL
translocation	NULL
but	NULL
not	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
1	NULL
enhancer-dependent	NULL
transcription	NULL
(	NULL
long	NULL
terminal	NULL
repeat	NULL
/transcription	NULL
factors	NULL
/lymphokines/T-cell	NULL
clone	NULL
/antigen	NULL
recognition	NULL
)	NULL
Uriel	NULL
HazAn*	NULL
,	NULL
Dominique	NULL
THomas*	NULL
,	NULL
JosE	NULL
ALcaMI*	NULL
,	NULL
Francoise	NULL
BACHELERIE*	NULL
,	NULL
NICOLE	NULL
IsRAEL*	NULL
,	NULL
Hans	NULL
YssEL	NULL
!	NULL

,	NULL
JEaAnN-Louis	NULL
VIRELIZIER**	NULL
,	NULL
AND	NULL
FERNANDO	NULL
ARENZANA-SEISDEDOS*	NULL
*Unite	NULL
d'Immunologie	NULL
Virale	NULL
,	NULL
Institut	NULL
Pasteur	NULL
,	NULL
28	NULL
rue	NULL
du	NULL
Dr.	NULL
Roux	NULL
,	NULL
75724	NULL
Paris	NULL
Cedex	NULL
15	NULL
,	NULL
France	NULL
:	NULL
;	NULL
and	NULL
*DNA	NULL
'	NULL
X	NULL
Research	NULL
Institute	NULL
,	NULL
901	NULL
California	NULL
Avenue	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
94304-1104	NULL
Communicated	NULL
by	NULL
Andre	NULL
Lwoff	NULL
,	NULL
June	NULL
27	NULL
,	NULL
1990	NULL
ABSTRACT	NULL
The	NULL
expression	NULL
of	NULL
transiently	NULL
transfected	NULL
expression	NULL
vectors	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
or	NULL
its	NULL
enhancer	NULL
sequence	NULL
and	NULL
the	NULL
translocation	NULL
of	NULL
the	NULL
HIV	NULL
enhancer-binding	NULL
protein	NULL
NF-	NULL
«	NULL
B	NULL
were	NULL
analyzed	NULL
in	NULL
two	NULL
human	NULL
T-cell	NULL
clones	NULL
stimulated	NULL
through	NULL
their	NULL
T-cell	NULL
receptor	NULL
complex	NULL
or	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
or	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
.	NULL

We	NULL
found	NULL
a	NULL
dissociation	NULL
of	NULL
NF-xB	NULL
translocation	NULL
from	NULL
transactivation	NULL
of	NULL
either	NULL
the	NULL
HIV	NULL
LTR	NULL
or	NULL
the	NULL
HIV	NULL
enhancer	NULL
.	NULL

Interleukin	NULL
2	NULL
induced	NULL
proliferation	NULL
but	NULL
not	NULL
NF-B	NULL
translocation	NULL
or	NULL
LTR	NULL
transactivation	NULL
.	NULL

Phorbol	NULL
ester	NULL
or	NULL
specific	NULL
antigen	NULL
recognition	NULL
induced	NULL
HIV	NULL
LTR	NULL
transactivation	NULL
,	NULL
whereas	NULL
stimulation	NULL
with	NULL
tumor	NULL
necrosis	NULL
factor	NULL
or	NULL
antibody	NULL
to	NULL
CD3	NULL
did	NULL
not	NULL
.	NULL

The	NULL
two	NULL
latter	NULL
signals	NULL
were	NULL
nevertheless	NULL
able	NULL
to	NULL
induce	NULL
NF-	NULL
«	NULL
B	NULL
translocation	NULL
with	NULL
a	NULL
pattern	NULL
in	NULL
the	NULL
band-shift	NULL
assay	NULL
indistinguishable	NULL
from	NULL
that	NULL
observed	NULL
using	NULL
phorbol	NULL
ester	NULL
.	NULL

Our	NULL
finding	NULL
that	NULL
induction	NULL
of	NULL
NF-xB	NULL
by	NULL
tumor	NULL
necrosis	NULL
factor	NULL
or	NULL
antibody	NULL
to	NULL
CD3	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
induce	NULL
HIV	NULL
enhancer-dependent	NULL
transcription	NULL
in	NULL
cloned	NULL
T	NULL
cells	NULL
contrasts	NULL
with	NULL
results	NULL
obtained	NULL
in	NULL
most	NULL
lymphoblastoid	NULL
T-cell	NULL
lines	NULL
and	NULL
indicates	NULL
that	NULL
normal	NULL
T	NULL
lymphocytes	NULL
differ	NULL
from	NULL
tumoral	NULL
T	NULL
cells	NULL
in	NULL
terms	NULL
of	NULL
requirements	NULL
for	NULL
HIV	NULL
LTR	NULL
activation	NULL
.	NULL

Furthermore	NULL
,	NULL
our	NULL
results	NULL
suggest	NULL
that	NULL
events	NULL
linked	NULL
to	NULL
T-cell	NULL
activation	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
NF-xB	NULL
translocation	NULL
per	NULL
se	NULL
,	NULL
induce	NULL
functional	NULL
interactions	NULL
of	NULL
the	NULL
complex	NULL
with	NULL
the	NULL
HIV	NULL
enhancer	NULL
.	NULL

Among	NULL
circulating	NULL
leukocytes	NULL
(	NULL
peripheral	NULL
blood	NULL
lympho-cytes	NULL
)	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
-seropositive	NULL
patients	NULL
,	NULL
CD4-positive	NULL
T	NULL
lymphocytes	NULL
represent	NULL
the	NULL
main	NULL
cell	NULL
type	NULL
infected	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Such	NULL
cells	NULL
,	NULL
when	NULL
cultured	NULL
in	NULL
vitro	NULL
,	NULL
show	NULL
very	NULL
little	NULL
,	NULL
if	NULL
any	NULL
,	NULL
HIV	NULL
replication	NULL
.	NULL

Virus	NULL
production	NULL
is	NULL
induced	NULL
in	NULL
peripheral	NULL
blood	NULL
lymphocyte	NULL
cultures	NULL
from	NULL
most	NULL
patients	NULL
by	NULL
stimulation	NULL
with	NULL
mitogens	NULL
,	NULL
such	NULL
as	NULL
phytohemagglutinin	NULL
or	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
)	NULL
(	NULL
2	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
transcriptional	NULL
activation	NULL
of	NULL
HIV	NULL
provirus	NULL
from	NULL
a	NULL
quiescent	NULL
state	NULL
in	NULL
resting	NULL
,	NULL
circulating	NULL
lymphocytes	NULL
is	NULL
under	NULL
the	NULL
control	NULL
of	NULL
cellular	NULL
genes	NULL
induced	NULL
during	NULL
T-cell	NULL
activation	NULL
,	NULL
as	NULL
has	NULL
been	NULL
discussed	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
molecular	NULL
events	NULL
linking	NULL
T-cell	NULL
activation	NULL
to	NULL
HIV	NULL
provirus	NULL
activation	NULL
is	NULL
essential	NULL
for	NULL
our	NULL
understanding	NULL
of	NULL
the	NULL
pathogenesis	NULL
of	NULL
AIDS	NULL
.	NULL

Most	NULL
of	NULL
our	NULL
knowledge	NULL
in	NULL
this	NULL
field	NULL
comes	NULL
from	NULL
the	NULL
study	NULL
of	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
activity	NULL
in	NULL
tumoral	NULL
lymphoblastoid	NULL
T-cell	NULL
lines	NULL
.	NULL

In	NULL
such	NULL
cell	NULL
systems	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
HIV	NULL
LTR	NULL
is	NULL
the	NULL
main	NULL
region	NULL
regulating	NULL
transcription	NULL
.	NULL

It	NULL
contains	NULL
a	NULL
10-base-pair	NULL
direct	NULL
repeat	NULL
enhancer	NULL
element	NULL
that	NULL
can	NULL
bind	NULL
and	NULL
respond	NULL
to	NULL
NF-	NULL
«	NULL
B-like	NULL
transcription	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
(	NULL
4	NULL
)	NULL
translocated	NULL
from	NULL
the	NULL
cytoplasm	NULL
upon	NULL
stimulation	NULL
with	NULL
PMA	NULL
or	NULL
mitogens	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Two	NULL
natural	NULL
cytokines	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

7861	NULL
(	NULL
TNF	NULL
)	NULL
and	NULL
lymphotoxin	NULL
(	NULL
LT	NULL
)	NULL
,	NULL
have	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
both	NULL
HIV	NULL
replication	NULL
and	NULL
HIV	NULL
LTR	NULL
transactivation	NULL
through	NULL
translocation	NULL
into	NULL
the	NULL
nucleus	NULL
of	NULL
NF-	NULL
«	NULL
B-like	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
that	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
HIV	NULL
enhancer	NULL
(	NULL
6-8	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
mutation	NULL
of	NULL
the	NULL
10-base-pair	NULL
repeat	NULL
sequence	NULL
that	NULL
binds	NULL
NF-	NULL
«	NULL
B	NULL
abolishes	NULL
mitogen-induced	NULL
HIV	NULL
LTR	NULL
transactivation	NULL
in	NULL
lymphoblastoid	NULL
T-cell	NULL
lines	NULL
(	NULL
5	NULL
)	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
understand	NULL
which	NULL
physiological	NULL
signals	NULL
induce	NULL
HIV	NULL
transcription	NULL
in	NULL
normal	NULL
T	NULL
lymphocytes	NULL
.	NULL

Indeed	NULL
,	NULL
mitogens	NULL
are	NULL
artificial	NULL
reagents	NULL
and	NULL
TNF	NULL
may	NULL
not	NULL
be	NULL
able	NULL
to	NULL
activate	NULL
resting	NULL
T	NULL
lymphocytes	NULL
that	NULL
do	NULL
not	NULL
express	NULL
detectable	NULL
TNF	NULL
receptors	NULL
(	NULL
9	NULL
)	NULL
.	NULL

A	NULL
physiological	NULL
event	NULL
that	NULL
can	NULL
activate	NULL
CD4-positive	NULL
T	NULL
lymphocytes	NULL
from	NULL
their	NULL
normal	NULL
resting	NULL
state	NULL
is	NULL
antigen	NULL
recognition	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Our	NULL
approach	NULL
has	NULL
been	NULL
to	NULL
use	NULL
as	NULL
an	NULL
experimental	NULL
system	NULL
,	NULL
CD4-positive	NULL
T-lymphocyte	NULL
cell	NULL
clones	NULL
maintained	NULL
in	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
-rich	NULL
medium	NULL
and	NULL
transfected	NULL
with	NULL
HIV	NULL
LTR	NULL
expression	NULL
vectors	NULL
.	NULL

The	NULL
advantages	NULL
of	NULL
this	NULL
cell	NULL
system	NULL
are	NULL
manifold	NULL
:	NULL
(	NULL
?	NULL
)	NULL

cloned	NULL
T	NULL
cells	NULL
are	NULL
not	NULL
tumoral	NULL
,	NULL
(	NULL
i	NULL
)	NULL
they	NULL
express	NULL
functional	NULL
membrane	NULL
receptors	NULL
,	NULL
(	NULL
ii	NULL
?	NULL
)	NULL

they	NULL
respond	NULL
to	NULL
and	NULL
produce	NULL
lymphokines	NULL
such	NULL
as	NULL
IL-2	NULL
,	NULL
TNF	NULL
,	NULL
LT	NULL
,	NULL
and	NULL
inter-feron-y	NULL
(	NULL
IFN-y	NULL
)	NULL
,	NULL
and	NULL
(	NULL
iv	NULL
)	NULL
they	NULL
can	NULL
be	NULL
directly	NULL
activated	NULL
by	NULL
specific	NULL
antigen	NULL
presentation	NULL
.	NULL

In	NULL
this	NULL
system	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
requirements	NULL
for	NULL
HIV	NULL
LTR	NULL
transactivation	NULL
are	NULL
different	NULL
from	NULL
those	NULL
reported	NULL
in	NULL
tumoral	NULL
T-cell	NULL
lines	NULL
.	NULL

MATERIAL	NULL
AND	NULL
METHODS	NULL
Cells	NULL
.	NULL

Clone	NULL
D106	NULL
(	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
M.	NULL
Agrapart	NULL
and	NULL
J.	NULL
J	NULL
.	NULL

Ballet	NULL
,	NULL
Hopital	NULL
St.	NULL
Louis	NULL
,	NULL
Paris	NULL
)	NULL
is	NULL
a	NULL
human	NULL
CD4-positive	NULL
,	NULL
CD3-positive	NULL
,	NULL
CD8-negative	NULL
T-cell	NULL
clone	NULL
that	NULL
specifically	NULL
responds	NULL
to	NULL
tetanus	NULL
toxoid	NULL
when	NULL
cocultured	NULL
with	NULL
autologous	NULL
macrophages	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Clone	NULL
SPB21	NULL
is	NULL
a	NULL
CD4-positive	NULL
,	NULL
CD3-positive	NULL
,	NULL
CD8-negative	NULL
human	NULL
T-cell	NULL
clone	NULL
that	NULL
was	NULL
selected	NULL
through	NULL
specific	NULL
proliferation	NULL
triggered	NULL
by	NULL
anti-T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
-CD3	NULL
monoclonal	NULL
antibody	NULL
(	NULL
mAb	NULL
)	NULL
3D6	NULL
(	NULL
12	NULL
)	NULL
.	NULL

After	NULL
thawing	NULL
,	NULL
SPB21	NULL
cells	NULL
and	NULL
irradiated	NULL
allogenic	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
were	NULL
stimulated	NULL
with	NULL
phytohemagglutinin	NULL
(	NULL
0.1	NULL
ug/mi	NULL
,	NULL
Wellcome	NULL
)	NULL
and	NULL
cocuitured	NULL
for	NULL
3	NULL
days	NULL
as	NULL
described	NULL
(	NULL
12	NULL
)	NULL
.	NULL

On	NULL
day	NULL
3	NULL
,	NULL
and	NULL
every	NULL
3	NULL
days	NULL
thereafter	NULL
,	NULL
recombinant	NULL
(	NULL
r	NULL
)	NULL
IL-2	NULL
(	NULL
Cetus	NULL
)	NULL
at	NULL
20	NULL
ng/ml	NULL
was	NULL
added	NULL
to	NULL
the	NULL
cultures	NULL
.	NULL

The	NULL
human	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
J-Jhan	NULL
,	NULL
a	NULL
subclone	NULL
of	NULL
the	NULL
Jurkat	NULL
cell	NULL
line	NULL
,	NULL
was	NULL
cultured	NULL
and	NULL
transfected	NULL
as	NULL
described	NULL
(	NULL
8	NULL
)	NULL
.	NULL

707/3	NULL
is	NULL
a	NULL
pre-B-cell	NULL
line	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Abbreviations	NULL
:	NULL
CAT	NULL
,	NULL
chloramphenicol	NULL
acetyltransferase	NULL
;	NULL
HIV	NULL
,	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
;	NULL
HEBP	NULL
,	NULL
HIV	NULL
enhancer	NULL
binding	NULL
protein	NULL
;	NULL
IFN-y	NULL
,	NULL
interferon-y	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
LT	NULL
,	NULL
lymphotoxin	NULL
;	NULL
LTR	NULL
,	NULL
long	NULL
terminal	NULL
repeat	NULL
;	NULL
Luc	NULL
,	NULL
luciferase	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
l3-acetate	NULL
;	NULL
TK	NULL
,	NULL
thymidine	NULL
kinase	NULL
;	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
;	NULL
r	NULL
,	NULL
recombinant	NULL
;	NULL
TCR	NULL
,	NULL
T-cell	NULL
receptor	NULL
;	NULL
CRE	NULL
,	NULL
cAMP-responsive	NULL
ele-ment	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
.	NULL

whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

7862	NULL
Immunology	NULL
:	NULL
Hazan	NULL
et	NULL
al	NULL
.	NULL

Lymphokine	NULL
Assays	NULL
.	NULL

Supernatants	NULL
from	NULL
cell	NULL
cultures	NULL
were	NULL
titrated	NULL
for	NULL
IFN-y	NULL
and	NULL
TNF/LT	NULL
production	NULL
with	NULL
standard	NULL
bioassays	NULL
as	NULL
described	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Culture	NULL
Medium	NULL
,	NULL
Lymphokines	NULL
,	NULL
and	NULL
Antibodies	NULL
.	NULL

Yssel	NULL
's	NULL
medium	NULL
,	NULL
an	NULL
Iscove	NULL
's	NULL
modified	NULL
Dulbecco	NULL
's	NULL
medium	NULL
(	NULL
GIBCO/	NULL
BRL	NULL
)	NULL
(	NULL
15	NULL
)	NULL
,	NULL
was	NULL
supplemented	NULL
with	NULL
1	NULL
%	NULL
heat-inactivated	NULL
pooled	NULL
human	NULL
AB	NULL
serum	NULL
.	NULL

PMA	NULL
was	NULL
purchased	NULL
from	NULL
Sigma	NULL
.	NULL

rIL-2	NULL
was	NULL
from	NULL
Cetus	NULL
.	NULL

Human	NULL
rTNF	NULL
and	NULL
neutralizing	NULL
rabbit	NULL
antisera	NULL
to	NULL
TNF	NULL
and	NULL
LT	NULL
were	NULL
a	NULL
gift	NULL
from	NULL
W.	NULL
Fiers	NULL
(	NULL
Rijksuni-versitat	NULL
,	NULL
Ghent	NULL
,	NULL
Belgium	NULL
)	NULL
.	NULL

Purified	NULL
anti-TNF	NULL
mAb	NULL
TE115	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
D.	NULL
Lando	NULL
(	NULL
Roussel-UCLAF	NULL
)	NULL
.	NULL

mAb	NULL
SPV	NULL
T3b	NULL
,	NULL
an	NULL
IgG2a	NULL
directed	NULL
against	NULL
CD3	NULL
molecule	NULL
(	NULL
16	NULL
)	NULL
,	NULL
was	NULL
used	NULL
as	NULL
crude	NULL
ascites	NULL
fluid	NULL
.	NULL

Plasmids	NULL
.	NULL

We	NULL
constructed	NULL
a	NULL
series	NULL
of	NULL
Luciferase	NULL
(	NULL
Luc	NULL
)	NULL
expression	NULL
vectors	NULL
(	NULL
17	NULL
)	NULL
under	NULL
the	NULL
control	NULL
of	NULL
various	NULL
HIV	NULL
LTR	NULL
fragments	NULL
or	NULL
of	NULL
the	NULL
weak	NULL
truncated	NULL
herpes	NULL
simplex	NULL
thymidine	NULL
kinase	NULL
(	NULL
TK	NULL
)	NULL
promoter	NULL
(	NULL
positions	NULL
-105	NULL
to	NULL
+51	NULL
)	NULL
.	NULL

The	NULL
HIV	NULL
LTR	NULL
fragment	NULL
[	NULL
Xho	NULL
I	NULL
(	NULL
-640	NULL
)	NULL
-HindIII	NULL
(	NULL
+78	NULL
)	NULL
]	NULL
containing	NULL
the	NULL
U3	NULL
and	NULL
R	NULL
regions	NULL
was	NULL
cloned	NULL
into	NULL
the	NULL
pC-Luc	NULL
plasmid	NULL
,	NULL
generating	NULL
pLTRX-Luc	NULL
.	NULL

A	NULL
shorter	NULL
LTR	NULL
fragment	NULL
[	NULL
Sca	NULL
I	NULL
(	NULL
-142	NULL
)	NULL
-HindIll	NULL
(	NULL
+78	NULL
)	NULL
]	NULL
was	NULL
cloned	NULL
in	NULL
pC-Luc	NULL
,	NULL
yielding	NULL
plasmid	NULL
pLTRS-Luc	NULL
.	NULL

The	NULL
p3enhTK-Luc	NULL
vector	NULL
was	NULL
constructed	NULL
by	NULL
cloning	NULL
the	NULL
270-base-pair	NULL
Bgl	NULL
II	NULL
(	NULL
Klenow	NULL
)	NULL
-Sal	NULL
I	NULL
fragment	NULL
of	NULL
plasmid	NULL
pHI-03TK-CAT	NULL
,	NULL
as	NULL
described	NULL
(	NULL
8	NULL
)	NULL
,	NULL
into	NULL
the	NULL
HindIlI	NULL
(	NULL
Klenow	NULL
)	NULL
-Sal	NULL
I	NULL
sites	NULL
of	NULL
the	NULL
pC-Luc	NULL
polylinker	NULL
(	NULL
17	NULL
)	NULL
.	NULL

This	NULL
vector	NULL
contains	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
HIV-enhancer	NULL
synthetic	NULL
oligonucleotide	NULL
described	NULL
below	NULL
in	NULL
the	NULL
band-shift	NULL
assay	NULL
.	NULL

Various	NULL
tat	NULL
expression	NULL
vectors	NULL
were	NULL
used	NULL
.	NULL

Vector	NULL
pLTRA-tat	NULL
contained	NULL
the	NULL
Ava	NULL
HIV	NULL
LTR	NULL
fragment	NULL
upstream	NULL
of	NULL
tat	NULL
cDNA	NULL
with	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
region	NULL
.	NULL

The	NULL
pCMV-tat	NULL
vector	NULL
contained	NULL
a	NULL
tat	NULL
cDNA	NULL
with	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
region	NULL
inserted	NULL
downstream	NULL
of	NULL
the	NULL
human	NULL
cytomegalovirus	NULL
immediate	NULL
early	NULL
enhancer/	NULL
promoter	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Finally	NULL
the	NULL
pLTRX-CAT	NULL
used	NULL
in	NULL
experiments	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
carries	NULL
the	NULL
bacterial	NULL
chloramphenicol	NULL
ace-tyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
Xho	NULL
I-HindlII	NULL
LTR	NULL
fragment	NULL
described	NULL
above	NULL
.	NULL

Cell	NULL
Transfection	NULL
.	NULL

D106	NULL
cells	NULL
(	NULL
2	NULL
x	NULL
10	NULL
``	NULL
cells	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
5-10	NULL
ug	NULL
of	NULL
plasmid	NULL
(	NULL
s	NULL
)	NULL
by	NULL
using	NULL
a	NULL
modified	NULL
DEAE-dextran	NULL
technique	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
dispatched	NULL
and	NULL
layered	NULL
on	NULL
autologous	NULL
irradiated	NULL
monocytes	NULL
used	NULL
as	NULL
antigen-presenting	NULL
cells	NULL
.	NULL

Tetanus	NULL
toxoid	NULL
(	NULL
purified	NULL
tetanus	NULL
toxoid	NULL
,	NULL
Bi-oMerieux	NULL
,	NULL
Charbonnier	NULL
les	NULL
Bains	NULL
,	NULL
France	NULL
)	NULL
was	NULL
used	NULL
at	NULL
10	NULL
ug/ml	NULL
.	NULL

Ten	NULL
days	NULL
after	NULL
thawing	NULL
SPB21	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10	NULL
``	NULL
to	NULL
1	NULL
x	NULL
10°	NULL
cells	NULL
)	NULL
were	NULL
transfected	NULL
with	NULL
20-30	NULL
ug	NULL
of	NULL
plasmid	NULL
(	NULL
s	NULL
)	NULL
by	NULL
electroporation	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
(	NULL
GIBCO/BRL	NULL
)	NULL
with	NULL
5	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
human	NULL
AB	NULL
serum	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
rIL-2	NULL
.	NULL

A	NULL
single	NULL
pulse	NULL
at	NULL
680	NULL
V/cm	NULL
and	NULL
1340	NULL
uF	NULL
was	NULL
done	NULL
.	NULL

After	NULL
the	NULL
electric	NULL
shock	NULL
,	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
same	NULL
plasmid	NULL
(	NULL
s	NULL
)	NULL
were	NULL
pooled	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
incubated	NULL
for	NULL
8	NULL
hr	NULL
,	NULL
before	NULL
stimulation	NULL
by	NULL
anti-CD3	NULL
(	NULL
ascites	NULL
fluid	NULL
dilution	NULL
,	NULL
1:500	NULL
)	NULL
,	NULL
rTNF	NULL
(	NULL
500	NULL
units/ml	NULL
)	NULL
,	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
,	NULL
or	NULL
rIL-2	NULL
(	NULL
20	NULL
ng/ml	NULL
)	NULL
.	NULL

Luc	NULL
and	NULL
CAT	NULL
Assays	NULL
.	NULL

These	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
8	NULL
,	NULL
17	NULL
)	NULL
18-20	NULL
hr	NULL
after	NULL
cell	NULL
stimulation	NULL
.	NULL

Luc	NULL
index	NULL
represents	NULL
the	NULL
Luc	NULL
activity	NULL
relative	NULL
to	NULL
the	NULL
cell	NULL
number	NULL
and	NULL
was	NULL
calculated	NULL
using	NULL
the	NULL
following	NULL
formula	NULL
:	NULL
(	NULL
Luc	NULL
cpm	NULL
-	NULL
background	NULL
cpm	NULL
)	NULL
/	NULL
(	NULL
number	NULL
of	NULL
living	NULL
cells	NULL
x	NULL
10	NULL
~*	NULL
)	NULL
.	NULL

Band-Shift	NULL
Assay	NULL
.	NULL

For	NULL
preparation	NULL
of	NULL
nuclear	NULL
proteins	NULL
,	NULL
SPB21	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
deprived	NULL
of	NULL
rIL-2	NULL
for	NULL
16-18	NULL
hr	NULL
before	NULL
being	NULL
stimulated	NULL
as	NULL
described	NULL
above	NULL
.	NULL

70Z/3	NULL
pre-B	NULL
cells	NULL
were	NULL
stimulated	NULL
by	NULL
PMA	NULL
(	NULL
25	NULL
ng/ml	NULL
)	NULL
,	NULL
thus	NULL
providing	NULL
bona	NULL
fide	NULL
NF-	NULL
«	NULL
B-positive	NULL
control	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
control	NULL
and	NULL
stimulated	NULL
cells	NULL
were	NULL
then	NULL
prepared	NULL
and	NULL
tested	NULL
as	NULL
described	NULL
(	NULL
8	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Double-stranded	NULL
oligonucleotides	NULL
corresponding	NULL
to	NULL
either	NULL
wild-type	NULL
or	NULL
mutated	NULL
enhancer	NULL
repeat	NULL
(	NULL
NF-	NULL
«	NULL
B-like	NULL
binding	NULL
site	NULL
)	NULL
of	NULL
HIV	NULL
LTR	NULL
enhancer	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
C.	NULL
Auffray	NULL
and	NULL
A.	NULL
Delaroche	NULL
,	NULL
Institut	NULL
d'Embriologie	NULL
,	NULL
Nogent	NULL
sur	NULL
Marne	NULL
,	NULL
France	NULL
)	NULL
or	NULL
to	NULL
the	NULL
immunoglobulin	NULL
«	NULL
chain	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
(	NULL
gift	NULL
from	NULL
A.	NULL
Israél	NULL
,	NULL
Institut	NULL
Pasteur	NULL
,	NULL
Paris	NULL
)	NULL
were	NULL
labeled	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
.	NULL

Specific	NULL
binding	NULL
was	NULL
controlled	NULL
by	NULL
competition	NULL
with	NULL
a	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
(	NULL
1990	NULL
)	NULL
50-fold	NULL
excess	NULL
of	NULL
either	NULL
unlabeled	NULL
HIV	NULL
enhancer	NULL
or	NULL
unlabeled	NULL
irrelevant	NULL
oligonucleotide	NULL
[	NULL
corresponding	NULL
to	NULL
the	NULL
cAMP-responsive	NULL
element	NULL
(	NULL
CRE	NULL
)	NULL
of	NULL
the	NULL
somatostatin	NULL
gene	NULL
(	NULL
19	NULL
)	NULL
,	NULL
a	NULL
gift	NULL
from	NULL
M.	NULL
Yaniv	NULL
(	NULL
Institut	NULL
Pasteur	NULL
,	NULL
Paris	NULL
)	NULL
]	NULL
.	NULL

Sequences	NULL
of	NULL
the	NULL
oligonucieotides	NULL
used	NULL
are	NULL
as	NULL
follows	NULL
:	NULL
HIV	NULL
enhancer	NULL
,	NULL
S'-AGCTTACAAGGGACTTTCCGCTGGG-GACTTTCCAGGGA-3	NULL
'	NULL
;	NULL
HIV	NULL
enhancer	NULL
mutant	NULL
(	NULL
mutated	NULL
sites	NULL
are	NULL
underlined	NULL
)	NULL
,	NULL
S	NULL
!	NULL

-ACTCACTTTCCGCTGECTITCACTT-TCC-3	NULL
'	NULL
;	NULL
immunoglobulin	NULL
«	NULL
-chain	NULL
enhancer	NULL
,	NULL
5-GACA-GAGGGGACTTTCCGAGAGG-3	NULL
'	NULL
;	NULL
somatostatin	NULL
CRE	NULL
,	NULL
5'-GTTGGCTGACGTCATCAAGCTA-3	NULL
'	NULL
.	NULL

RESULTS	NULL
Cells	NULL
of	NULL
the	NULL
D106	NULL
clone	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
an	NULL
HIV-LTR-CAT	NULL
construct	NULL
and	NULL
specifically	NULL
stimulated	NULL
with	NULL
tetanus	NULL
toxoid	NULL
.	NULL

An	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
was	NULL
observed	NULL
in	NULL
antigen-stimulated	NULL
cultures	NULL
,	NULL
and	NULL
a	NULL
further	NULL
increase	NULL
was	NULL
found	NULL
in	NULL
stimulated	NULL
cells	NULL
cotransfected	NULL
with	NULL
the	NULL
HIV-LTR-tat	NULL
vec-tor	NULL
,	NULL
as	NULL
can	NULL
be	NULL
seen	NULL
in	NULL
the	NULL
representative	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

It	NULL
can	NULL
be	NULL
seen	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
that	NULL
the	NULL
basal	NULL
level	NULL
of	NULL
LTR	NULL
activity	NULL
(	NULL
pLTRS-Luc	NULL
vector	NULL
)	NULL
was	NULL
remarkably	NULL
low	NULL
in	NULL
T-cell	NULL
clone	NULL
SPB21	NULL
and	NULL
was	NULL
poorly	NULL
enhanced	NULL
by	NULL
cotransfection	NULL
of	NULL
a	NULL
vector	NULL
permitting	NULL
tat	NULL
protein	NULL
expression	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
autologous	NULL
LTR	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
cotransfection	NULL
of	NULL
fat	NULL
driven	NULL
by	NULL
the	NULL
strong	NULL
cytomegalovirus	NULL
immediate	NULL
early	NULL
promoter	NULL
(	NULL
20	NULL
)	NULL
led	NULL
to	NULL
transactivation	NULL
of	NULL
the	NULL
HIV-LTR-Luc	NULL
vector	NULL
.	NULL

We	NULL
tested	NULL
the	NULL
effects	NULL
of	NULL
PMA	NULL
and	NULL
rTNF	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
LTR-Luc	NULL
constructs	NULL
electroporated	NULL
with	NULL
or	NULL
without	NULL
an	NULL
LTR-tat	NULL
expression	NULL
vector	NULL
.	NULL

Fig	NULL
.	NULL

2	NULL
shows	NULL
that	NULL
PMA	NULL
stimulated	NULL
activity	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
,	NULL
an	NULL
effect	NULL
further	NULL
increased	NULL
by	NULL
cotransfection	NULL
of	NULL
an	NULL
LTR-tat	NULL
vector	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
was	NULL
unable	NULL
to	NULL
induce	NULL
HIV	NULL
LTR	NULL
transactivation	NULL
,	NULL
even	NULL
when	NULL
cotransfected	NULL
with	NULL
pLTR-tat	NULL
,	NULL
which	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
synergize	NULL
in	NULL
the	NULL
system	NULL
.	NULL

In	NULL
parallel	NULL
experiments	NULL
,	NULL
the	NULL
same	NULL
o	NULL
t	NULL
#	NULL
9	NULL
?	NULL

Fig	NULL
.	NULL

1	NULL
.	NULL

-	NULL
Antigen	NULL
presentation	NULL
induces	NULL
HIV	NULL
LTR	NULL
transactivation	NULL
in	NULL
the	NULL
D106	NULL
T-cell	NULL
clone	NULL
.	NULL

The	NULL
pLTRX-CAT	NULL
vector	NULL
was	NULL
transfected	NULL
alone	NULL
or	NULL
cotransfected	NULL
with	NULL
a	NULL
pLTR-tat	NULL
expression	NULL
vector	NULL
into	NULL
the	NULL
D106	NULL
T-cell	NULL
clone	NULL
by	NULL
using	NULL
DEAE-dextran	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

After	NULL
transfec-tion	NULL
,	NULL
T	NULL
cells	NULL
were	NULL
cocultured	NULL
with	NULL
adherent	NULL
autologous	NULL
monocytes	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
+	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
of	NULL
tetanus	NULL
toxoid	NULL
(	NULL
10	NULL
ug/ml	NULL
)	NULL
.	NULL

CAT	NULL
activity	NULL
was	NULL
measured	NULL
in	NULL
cell	NULL
lysates	NULL
24	NULL
hr	NULL
after	NULL
stimulation	NULL
.	NULL

Figures	NULL
at	NULL
the	NULL
top	NULL
of	NULL
columns	NULL
represent	NULL
fold	NULL
amplification	NULL
relative	NULL
to	NULL
CAT	NULL
conversion	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
antigen	NULL
stimulation	NULL
.	NULL

Immunology	NULL
:	NULL
Hazan	NULL
et	NULL
al	NULL
.	NULL

Luc	NULL
index	NULL
(	NULL
x	NULL
10d	NULL
)	NULL
None	NULL
PMA	NULL
rTNF	NULL
Inducer	NULL
None	NULL
PMA	NULL
rTNF	NULL
-	NULL
None	NULL
None	NULL
rTNF	NULL
Cotransfection	NULL
None	NULL
pLTRA-tat	NULL
pCMV-tat	NULL
None	NULL
Cells	NULL
SPB21	NULL
J-JHAN	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

HIV	NULL
LTR	NULL
activity	NULL
in	NULL
the	NULL
SPB21	NULL
T-cell	NULL
clone	NULL
after	NULL
elec-	NULL
troporation	NULL
of	NULL
the	NULL
pLTRS-Luc	NULL
vector	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
by	NULL
PMA	NULL
or	NULL
rTNF	NULL
without	NULL
(	NULL
®	NULL
)	NULL
or	NULL
with	NULL
(	NULL
@	NULL
)	NULL
cotransfection	NULL
of	NULL
pLTRA-tat	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
cotransfection	NULL
of	NULL
pCMV-tat	NULL
is	NULL
also	NULL
shown	NULL
(	NULL
@	NULL
)	NULL
.	NULL

The	NULL
same	NULL
preparation	NULL
of	NULL
rTNF	NULL
(	NULL
500	NULL
units/ml	NULL
)	NULL
was	NULL
used	NULL
to	NULL
enhance	NULL
expression	NULL
of	NULL
the	NULL
pLTRS-Luc	NULL
vector	NULL
transfected	NULL
alone	NULL
in	NULL
the	NULL
J-Jhan	NULL
T-lympho-blastoid	NULL
cell	NULL
line	NULL
(	NULL
0	NULL
)	NULL
.	NULL

Figures	NULL
at	NULL
the	NULL
top	NULL
of	NULL
columns	NULL
represent	NULL
fold	NULL
amplification	NULL
relative	NULL
to	NULL
Luc	NULL
expression	NULL
in	NULL
unstimulated	NULL
cells	NULL
transfected	NULL
with	NULL
pLTRS-Luc	NULL
alone	NULL
.	NULL

preparation	NULL
of	NULL
rT	NULL
NF	NULL
was	NULL
able	NULL
to	NULL
induce	NULL
LTR	NULL
transactivation	NULL
in	NULL
the	NULL
human	NULL
lymphoblastoid	NULL
T-cell	NULL
line	NULL
J-Jhan	NULL
,	NULL
as	NULL
reported	NULL
(	NULL
8	NULL
)	NULL
.	NULL

No	NULL
transactivation	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
was	NULL
observed	NULL
in	NULL
SPB21	NULL
clone	NULL
stimulated	NULL
by	NULL
anti-CD3	NULL
antibody	NULL
or	NULL
rIL-2	NULL
.	NULL

Stimulation	NULL
with	NULL
antibody	NULL
to	NULL
CD3	NULL
induced	NULL
T-cell	NULL
activation	NULL
,	NULL
as	NULL
measured	NULL
by	NULL
cell	NULL
proliferation	NULL
and	NULL
secretion	NULL
of	NULL
TNF	NULL
,	NULL
LT	NULL
,	NULL
and	NULL
IFN-y	NULL
,	NULL
but	NULL
did	NULL
not	NULL
stimulate	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
LTR	NULL
(	NULL
see	NULL
Figs	NULL
.	NULL

3	NULL
and	NULL
4	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
or	NULL
rIL-2	NULL
was	NULL
similarly	NULL
ineffective	NULL
(	NULL
mean	NULL
of	NULL
amplification	NULL
,	NULL
0.9	NULL
ranging	NULL
from	NULL
0.7-	NULL
to	NULL
2-fold	NULL
;	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
PMA	NULL
induced	NULL
both	NULL
lymphokine	NULL
secretion	NULL
and	NULL
activation	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
the	NULL
above	NULL
described	NULL
signals	NULL
on	NULL
HIV	NULL
enhancer	NULL
binding	NULL
protein	NULL
(	NULL
HEBP	NULL
)	NULL
induction	NULL
in	NULL
the	NULL
SPB21	NULL
clone	NULL
,	NULL
compared	NULL
to	NULL
their	NULL
ability	NULL
to	NULL
stimulate	NULL
cell	NULL
proliferation	NULL
and	NULL
lymphokine	NULL
production	NULL
,	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Addition	NULL
of	NULL
rIL-2	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
(	NULL
1990	NULL
)	NULL
7863	NULL
induced	NULL
intense	NULL
cell	NULL
proliferation	NULL
,	NULL
but	NULL
very	NULL
little	NULL
(	NULL
not	NULL
detectable	NULL
in	NULL
most	NULL
experiments	NULL
)	NULL
induction	NULL
of	NULL
HEBP	NULL
,	NULL
TNF	NULL
,	NULL
LT	NULL
,	NULL
or	NULL
IFN-y	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
stimulation	NULL
with	NULL
PMA	NULL
,	NULL
rTNF	NULL
,	NULL
or	NULL
anti-CD3	NULL
mAb	NULL
always	NULL
resulted	NULL
in	NULL
a	NULL
clear	NULL
induction	NULL
of	NULL
a	NULL
specific	NULL
HEBP	NULL
of	NULL
comparable	NULL
intensity	NULL
whatever	NULL
the	NULL
inducer	NULL
used	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
CD3	NULL
stimulation	NULL
induced	NULL
modest	NULL
,	NULL
but	NULL
clearly	NULL
detectable	NULL
proliferation	NULL
(	NULL
proliferation	NULL
index	NULL
range	NULL
from	NULL
3	NULL
to	NULL
5	NULL
)	NULL
and	NULL
also	NULL
secretion	NULL
of	NULL
TNF/LT	NULL
and	NULL
IFN-y	NULL
.	NULL

However	NULL
,	NULL
complete	NULL
neutralization	NULL
of	NULL
TNF	NULL
and	NULL
LT	NULL
by	NULL
specific	NULL
antibodies	NULL
during	NULL
stimulation	NULL
by	NULL
anti-CD3	NULL
did	NULL
not	NULL
significantly	NULL
decrease	NULL
HEBP	NULL
induction	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
shows	NULL
a	NULL
representative	NULL
experiment	NULL
in	NULL
which	NULL
HEBP	NULL
induction	NULL
and	NULL
transactivation	NULL
of	NULL
either	NULL
HIV-LTR	NULL
or	NULL
enhancer	NULL
TK-Luc	NULL
vectors	NULL
were	NULL
performed	NULL
in	NULL
parallel	NULL
,	NULL
using	NULL
the	NULL
same	NULL
culture	NULL
conditions	NULL
.	NULL

Cells	NULL
used	NULL
for	NULL
band-shift	NULL
assay	NULL
were	NULL
thus	NULL
electroporated	NULL
without	NULL
plasmid	NULL
.	NULL

We	NULL
had	NULL
observed	NULL
that	NULL
T-cell	NULL
clones	NULL
tended	NULL
to	NULL
release	NULL
TNF	NULL
and	NULL
LT	NULL
transiently	NULL
in	NULL
the	NULL
hours	NULL
after	NULL
electroporation	NULL
.	NULL

To	NULL
avoid	NULL
NF-KB	NULL
induction	NULL
by	NULL
TNF/LT	NULL
before	NULL
stimulation	NULL
,	NULL
we	NULL
performed	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
in	NULL
the	NULL
continuous	NULL
presence	NULL
of	NULL
excess	NULL
neutralizing	NULL
anti-TNF	NULL
and	NULL
anti-LT	NULL
antibodies	NULL
before	NULL
washing	NULL
and	NULL
stimulation	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
no	NULL
TNF/LT	NULL
activity	NULL
was	NULL
detectable	NULL
at	NULL
any	NULL
time	NULL
before	NULL
stimulation	NULL
.	NULL

Supernatants	NULL
of	NULL
unstimulated	NULL
cultures	NULL
remained	NULL
TNF/LT	NULL
-negative	NULL
after	NULL
removal	NULL
of	NULL
the	NULL
neutralizing	NULL
antibodies	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
culture	NULL
at	NULL
that	NULL
stage	NULL
induced	NULL
TNF	NULL
and	NULL
LT	NULL
secretion	NULL
.	NULL

It	NULL
can	NULL
be	NULL
seen	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
that	NULL
comparable	NULL
levels	NULL
of	NULL
a	NULL
specific	NULL
binding	NULL
on	NULL
the	NULL
HIV-enhancer	NULL
oligonucleotide	NULL
and	NULL
lymphokine	NULL
secretion	NULL
were	NULL
obtained	NULL
with	NULL
the	NULL
three	NULL
inducers	NULL
(	NULL
anti-CD3	NULL
,	NULL
rTNF	NULL
,	NULL
and	NULL
PMA	NULL
)	NULL
.	NULL

It	NULL
was	NULL
again	NULL
observed	NULL
that	NULL
PMA	NULL
,	NULL
but	NULL
not	NULL
anti-CD3	NULL
antibody	NULL
or	NULL
rTNF	NULL
,	NULL
induced	NULL
transactivation	NULL
of	NULL
the	NULL
two	NULL
vectors	NULL
used	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

5	NULL
shows	NULL
that	NULL
the	NULL
migration	NULL
patterns	NULL
induced	NULL
by	NULL
the	NULL
anti-CD3	NULL
antibody	NULL
,	NULL
rTNF	NULL
,	NULL
and	NULL
PMA	NULL
were	NULL
indistinguishable	NULL
from	NULL
one	NULL
another	NULL
and	NULL
from	NULL
that	NULL
of	NULL
bona	NULL
fide	NULL
NF-	NULL
«	NULL
B	NULL
protein	NULL
induced	NULL
in	NULL
70Z2/3	NULL
pre-B	NULL
cells	NULL
by	NULL
PMA	NULL
(	NULL
13	NULL
)	NULL
.	NULL

DESCUSSION	NULL
The	NULL
present	NULL
report	NULL
demonstrates	NULL
that	NULL
antigen	NULL
recognition	NULL
by	NULL
a	NULL
human	NULL
T-cell	NULL
clone	NULL
results	NULL
in	NULL
transactivation	NULL
of	NULL
the	NULL
HIV-LTR	NULL
vectors	NULL
transfected	NULL
in	NULL
such	NULL
nontumoral	NULL
cells	NULL
.	NULL

This	NULL
was	NULL
observed	NULL
in	NULL
cultures	NULL
of	NULL
a	NULL
CD4-positive	NULL
tetanus-toxoid-specific	NULL
T-cell	NULL
clone	NULL
Enhancer	NULL
W	NULL
M	NULL
W	NULL
M	NULL
W	NULL
M	NULL
W	NULL
M	NULL
W	NULL
M	NULL
W	NULL
M	NULL
probe	NULL
m	NULL
a	NULL
-	NULL
m	NULL
a	NULL
=-	NULL
m	NULL
a	NULL
--	NULL
e	NULL
«	NULL
i	NULL
i	NULL
g	NULL
a	NULL
g	NULL
Competition	NULL
o	NULL
§	NULL
&	NULL
oo	NULL
§	NULL
&	NULL
oo	NULL
5	NULL
&	NULL
o	NULL
o	NULL
5	NULL
#	NULL
o	NULL
o	NULL
5	NULL
§	NULL
oo	NULL
5	NULL
&	NULL
o	NULL
s	NULL
»	NULL
6	NULL
%	NULL
«	NULL
#	NULL
=	NULL
w=	NULL
®	NULL
#	NULL
semuft-®	NULL
hay	NULL
#	NULL
#	NULL
t	NULL
but	NULL
bg	NULL
=	NULL
w	NULL
«	NULL
Inducer	NULL
None	NULL
rIL2	NULL
PMA	NULL
rTNF	NULL
e-CD3	NULL
w-CD3	NULL
e-TNF/LT	NULL
Proliferation	NULL
index	NULL
1	NULL
66	NULL
2	NULL
2	NULL
3.5	NULL
11	NULL
TNF/LT	NULL
(	NULL
U/m1	NULL
)	NULL
-	NULL
«	NULL
2	NULL
<	NULL
2	NULL
128	NULL
ND	NULL
48	NULL
<	NULL
2	NULL
IFN-y	NULL
(	NULL
U/m1	NULL
)	NULL
<	NULL
3	NULL
<	NULL
3	NULL
18	NULL
9	NULL
36	NULL
24	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Identification	NULL
of	NULL
specific	NULL
nuclear	NULL
factors	NULL
binding	NULL
to	NULL
the	NULL
HIV	NULL
enhancer	NULL
in	NULL
SPB21	NULL
cells	NULL
incubated	NULL
for	NULL
16	NULL
hr	NULL
with	NULL
PMA	NULL
,	NULL
rTNF	NULL
,	NULL
rIL-2	NULL
,	NULL
or	NULL
anti-CD3	NULL
(	NULL
a-CD3	NULL
)	NULL
.	NULL

Polyclonal	NULL
antibodies	NULL
to	NULL
TNF	NULL
(	NULL
a-TNF	NULL
)	NULL
and	NULL
LT	NULL
(	NULL
a-LT	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
cell	NULL
culture	NULL
before	NULL
stimulation	NULL
with	NULL
a-CD3	NULL
.	NULL

Band-shift	NULL
assay	NULL
was	NULL
performed	NULL
using	NULL
either	NULL
wild-type	NULL
(	NULL
W	NULL
)	NULL
or	NULL
mutated	NULL
(	NULL
M	NULL
)	NULL
labeled	NULL
HIV	NULL
enhancer	NULL
probe	NULL
.	NULL

The	NULL
specific	NULL
band	NULL
is	NULL
shown	NULL
by	NULL
an	NULL
arrow	NULL
.	NULL

Culture	NULL
supernatants	NULL
were	NULL
collected	NULL
16	NULL
hr	NULL
after	NULL
stimulation	NULL
for	NULL
analysis	NULL
of	NULL
TNF/LT	NULL
(	NULL
ND	NULL
,	NULL
TNF/LT	NULL
activity	NULL
was	NULL
not	NULL
determined	NULL
when	NULL
rTNF	NULL
was	NULL
used	NULL
as	NULL
inducer	NULL
)	NULL
and	NULL
IFN-y	NULL
.	NULL

Proliferation	NULL
index	NULL
is	NULL
the	NULL
ratio	NULL
of	NULL
[	NULL
}	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
by	NULL
induced	NULL
cells	NULL
relative	NULL
to	NULL
unstimulated	NULL
cells	NULL
.	NULL

U/ml	NULL
,	NULL
unit	NULL
(	NULL
s	NULL
)	NULL
/ml	NULL
;	NULL
Enh	NULL
.	NULL

,	NULL
enhancer	NULL
.	NULL

7864	NULL
Immunology	NULL
:	NULL
Hazan	NULL
et	NULL
al	NULL
.	NULL

¥	NULL
W	NULL
U	NULL
tuh	NULL
ss	NULL
wat	NULL
tah	NULL
tas	NULL
wt	NULL
ss	NULL
Ct	NULL
INDUCER	NULL
None	NULL
PMA	NULL
-	NULL
rTNF	NULL
«	NULL
-CD3	NULL
B	NULL
no	NULL
“	NULL
20	NULL
Q	NULL
L	NULL
15	NULL
i	NULL
``	NULL
)	NULL
R	NULL
E	NULL
10	NULL
§	NULL
3	NULL
t	NULL
x	NULL
1	NULL
\	NULL
x	NULL
1.1	NULL
.	NULL

\mss	NULL
SS	NULL
Sy	NULL
-	NULL
»	NULL
INDUCER	NULL
None	NULL
-	NULL
PMA	NULL
-	NULL
rTNF	NULL
a-CD3	NULL
TNF/LT	NULL
(	NULL
U/mi	NULL
)	NULL
|	NULL
<	NULL
2	NULL
128	NULL
ND	NULL
64	NULL
fe	NULL
16	NULL
x	NULL
3.5	NULL
'	NULL
o	NULL
3	NULL
a	NULL
10	NULL
T	NULL
C	NULL
&	NULL
bel	NULL
_J	NULL
0	NULL
INDUCER	NULL
_	NULL
None	NULL
PMA	NULL
-	NULL
rTNF	NULL
a-CD3	NULL
TNF/LT	NULL
(	NULL
U/mi	NULL
)	NULL
<	NULL
2	NULL
48	NULL
ND	NULL
128	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

-	NULL
Comparison	NULL
of	NULL
band-shift	NULL
assay	NULL
and	NULL
LTR	NULL
transactivation	NULL
results	NULL
obtained	NULL
in	NULL
parallel	NULL
experiments	NULL
after	NULL
electroporation	NULL
of	NULL
SPB21	NULL
cells	NULL
.	NULL

The	NULL
same	NULL
preparation	NULL
of	NULL
inducers	NULL
was	NULL
used	NULL
to	NULL
stimulate	NULL
the	NULL
three	NULL
experimental	NULL
groups	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Band-shift	NULL
assay	NULL
.	NULL

Cells	NULL
were	NULL
electroporated	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
plasmid	NULL
(	NULL
mock	NULL
transfection	NULL
)	NULL
,	NULL
pooled	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
subcultured	NULL
in	NULL
medium	NULL
containing	NULL
both	NULL
monoclonal	NULL
anti-TNF	NULL
antibody	NULL
and	NULL
polyclonal	NULL
anti-LT	NULL
antibody	NULL
for	NULL
8	NULL
hr	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
washed	NULL
extensively	NULL
to	NULL
eliminate	NULL
neutralizing	NULL
antibodies	NULL
to	NULL
TNF	NULL
and	NULL
LT	NULL
and	NULL
stimulated	NULL
for	NULL
an	NULL
additional	NULL
period	NULL
of	NULL
8	NULL
hr	NULL
.	NULL

Labeled	NULL
HIV	NULL
enhancer	NULL
oligonucleotide	NULL
probes	NULL
,	NULL
wild-type	NULL
(	NULL
W	NULL
)	NULL
or	NULL
mutated	NULL
(	NULL
M	NULL
)	NULL
,	NULL
were	NULL
used	NULL
to	NULL
localize	NULL
the	NULL
specific	NULL
band	NULL
(	NULL
arrow	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
HIV	NULL
LTR	NULL
activity	NULL
.	NULL

Cells	NULL
were	NULL
electroporated	NULL
with	NULL
pLTRS-Luc	NULL
+	NULL
pLTRA-tat	NULL
(	NULL
@	NULL
)	NULL
or	NULL
p3enhTK-Luc	NULL
(	NULL
®	NULL
)	NULL
.	NULL

Culture	NULL
conditions	NULL
and	NULL
stimulation	NULL
as	NULL
described	NULL
in	NULL
A	NULL
except	NULL
that	NULL
cell	NULL
lysates	NULL
for	NULL
Luc	NULL
assay	NULL
were	NULL
prepared	NULL
16	NULL
hr	NULL
after	NULL
cell	NULL
stimulation	NULL
.	NULL

Figures	NULL
at	NULL
the	NULL
top	NULL
of	NULL
columns	NULL
represent	NULL
fold	NULL
amplification	NULL
relative	NULL
to	NULL
unstimulated	NULL
cells	NULL
.	NULL

U/ml	NULL
,	NULL
unit	NULL
(	NULL
s	NULL
)	NULL
/ml	NULL
;	NULL
«	NULL
-CD3	NULL
,	NULL
anti-CD3	NULL
.	NULL

stimulated	NULL
with	NULL
antigen	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
autologous	NULL
adherent	NULL
monocytes	NULL
.	NULL

This	NULL
observation	NULL
,	NULL
obtained	NULL
with	NULL
a	NULL
pure	NULL
cell	NULL
population	NULL
directly	NULL
triggered	NULL
by	NULL
tetanus	NULL
toxoid	NULL
antigen	NULL
through	NULL
the	NULL
TCR-CD3	NULL
complex	NULL
,	NULL
confirms	NULL
and	NULL
extends	NULL
previously	NULL
reported	NULL
data	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Indeed	NULL
HIV	NULL
replication	NULL
has	NULL
been	NULL
found	NULL
to	NULL
be	NULL
enhanced	NULL
in	NULL
tetanus-toxoid-stimulated	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
infected	NULL
with	NULL
HIV	NULL
(	NULL
21	NULL
)	NULL
,	NULL
and	NULL
HIV-LTR	NULL
vectors	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
induced	NULL
in	NULL
primary	NULL
T-cell	NULL
blasts	NULL
obtained	NULL
after	NULL
stimulation	NULL
with	NULL
purified	NULL
protein	NULL
derivative	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
(	NULL
1990	NULL
)	NULL
¥	NULL
V	NULL
¥	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Band-shift	NULL
assay	NULL
using	NULL
oligonucleotide	NULL
probes	NULL
with	NULL
the	NULL
sequences	NULL
of	NULL
either	NULL
the	NULL
immunoglobulin	NULL
«	NULL
(	NULL
Ig-	NULL
«	NULL
)	NULL
chain	NULL
(	NULL
A	NULL
)	NULL
or	NULL
the	NULL
HIV	NULL
enhancer	NULL
(	NULL
B	NULL
)	NULL
in	NULL
nuclear	NULL
extracts	NULL
from	NULL
the	NULL
70Z/3	NULL
cell	NULL
line	NULL
stimulated	NULL
with	NULL
PMA	NULL
or	NULL
SPB21	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
,	NULL
rTNF	NULL
,	NULL
or	NULL
anti-CD3	NULL
(	NULL
a-CD3	NULL
)	NULL
.	NULL

Three	NULL
types	NULL
of	NULL
HIV-LTR-Luc	NULL
vectors	NULL
were	NULL
transfected	NULL
into	NULL
a	NULL
CD4-positive	NULL
IL-2-dependent	NULL
T-cell	NULL
clone	NULL
(	NULL
SPB21	NULL
)	NULL
that	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
soluble	NULL
anti-CD3	NULL
antibody	NULL
(	NULL
23	NULL
)	NULL
to	NULL
secrete	NULL
TNF	NULL
,	NULL
LT	NULL
,	NULL
and	NULL
IFN-y	NULL
.	NULL

In	NULL
this	NULL
cell	NULL
system	NULL
,	NULL
such	NULL
stimulation	NULL
did	NULL
not	NULL
result	NULL
in	NULL
detectable	NULL
activation	NULL
of	NULL
the	NULL
LTR	NULL
using	NULL
various	NULL
transfected	NULL
vectors	NULL
,	NULL
despite	NULL
evidence	NULL
of	NULL
cell	NULL
activation	NULL
.	NULL

rIL-2	NULL
induced	NULL
intense	NULL
cell	NULL
proliferation	NULL
but	NULL
no	NULL
LTR	NULL
transactivation	NULL
.	NULL

Addition	NULL
of	NULL
rTNF	NULL
did	NULL
not	NULL
modify	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
vectors	NULL
used	NULL
.	NULL

These	NULL
negative	NULL
results	NULL
were	NULL
not	NULL
due	NULL
to	NULL
an	NULL
intrinsic	NULL
inability	NULL
of	NULL
the	NULL
T-cell	NULL
clone	NULL
environment	NULL
to	NULL
permit	NULL
transactivation	NULL
of	NULL
the	NULL
HIV	NULL
LTR	NULL
,	NULL
since	NULL
it	NULL
clearly	NULL
responded	NULL
to	NULL
PMA	NULL
stimulation	NULL
.	NULL

Indeed	NULL
,	NULL
PMA	NULL
induced	NULL
activation	NULL
of	NULL
the	NULL
three	NULL
vectors	NULL
used	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
region	NULL
upstream	NULL
of	NULL
position	NULL
-142	NULL
is	NULL
not	NULL
necessary	NULL
for	NULL
PMA	NULL
induction	NULL
and	NULL
that	NULL
HIV	NULL
enhancer	NULL
sequences	NULL
played	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
response	NULL
to	NULL
PMA	NULL
in	NULL
our	NULL
cell	NULL
system	NULL
.	NULL

Our	NULL
results	NULL
,	NULL
obtained	NULL
in	NULL
a	NULL
normal	NULL
T-cell	NULL
clone	NULL
,	NULL
differ	NULL
from	NULL
those	NULL
reported	NULL
in	NULL
tumor	NULL
cell	NULL
lines	NULL
.	NULL

In	NULL
Jurkat	NULL
cells	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
stimulation	NULL
with	NULL
immobilized	NULL
OKT3	NULL
antibody	NULL
to	NULL
CD3	NULL
is	NULL
sufficient	NULL
to	NULL
induce	NULL
HIV	NULL
LTR	NULL
transactivation	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
our	NULL
laboratory	NULL
(	NULL
8	NULL
)	NULL
and	NULL
other	NULL
groups	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
have	NULL
found	NULL
that	NULL
stimulation	NULL
with	NULL
rFNF	NULL
alone	NULL
is	NULL
able	NULL
to	NULL
stimulate	NULL
HIV	NULL
transcription	NULL
in	NULL
tumor	NULL
T-cell	NULL
lines	NULL
.	NULL

CD3	NULL
stimulation	NULL
and	NULL
rTNF	NULL
induced	NULL
HEBP	NULL
in	NULL
SPB21	NULL
cells	NULL
in	NULL
a	NULL
manner	NULL
similar	NULL
to	NULL
PMA	NULL
.	NULL

HEBP	NULL
induction	NULL
by	NULL
anti-CD3	NULL
antibody	NULL
was	NULL
not	NULL
a	NULL
consequence	NULL
of	NULL
endogenous	NULL
TNF/LT	NULL
secretion	NULL
,	NULL
since	NULL
complete	NULL
neutralization	NULL
of	NULL
TNF	NULL
and	NULL
LT	NULL
by	NULL
specific	NULL
antisera	NULL
did	NULL
not	NULL
significantly	NULL
diminish	NULL
CD3-triggered	NULL
HEBP	NULL
induction	NULL
.	NULL

As	NULL
neutralization	NULL
of	NULL
TNF	NULL
in	NULL
cell	NULL
cultures	NULL
is	NULL
highly	NULL
efficient	NULL
,	NULL
this	NULL
indicates	NULL
that	NULL
CD3	NULL
stimulation	NULL
induces	NULL
HEBP	NULL
through	NULL
a	NULL
pathway	NULL
at	NULL
least	NULL
partially	NULL
independent	NULL
of	NULL
autocrine	NULL
secretion	NULL
of	NULL
TNF	NULL
and	NULL
LT	NULL
.	NULL

It	NULL
should	NULL
be	NULL
noted	NULL
that	NULL
rIL-2	NULL
induced	NULL
intense	NULL
proliferation	NULL
but	NULL
showed	NULL
a	NULL
very	NULL
modest	NULL
and	NULL
variable	NULL
effect	NULL
on	NULL
HEBP	NULL
induction	NULL
in	NULL
our	NULL
T-cell	NULL
clone	NULL
.	NULL

Thus	NULL
T-cell	NULL
proliferation	NULL
per	NULL
se	NULL
can	NULL
be	NULL
dissociated	NULL
from	NULL
HEBP	NULL
induction	NULL
and	NULL
HIV	NULL
LTR	NULL
transactivation	NULL
.	NULL

Immunology	NULL
:	NULL
Hazan	NULL
et	NULL
al	NULL
.	NULL

It	NULL
remains	NULL
to	NULL
be	NULL
understood	NULL
why	NULL
CD3	NULL
simulation	NULL
and	NULL
rTNF	NULL
induced	NULL
HEBP	NULL
but	NULL
not	NULL
LTR	NULL
transactivation	NULL
,	NULL
whereas	NULL
PMA	NULL
did	NULL
both	NULL
.	NULL

To	NULL
explain	NULL
this	NULL
surprising	NULL
difference	NULL
,	NULL
two	NULL
hypotheses	NULL
can	NULL
be	NULL
envisaged	NULL
.	NULL

One	NULL
is	NULL
that	NULL
PMA	NULL
,	NULL
known	NULL
to	NULL
induce	NULL
a	NULL
wide	NULL
repertoire	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
25	NULL
)	NULL
,	NULL
could	NULL
activate	NULL
,	NULL
apart	NULL
from	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
efficient	NULL
in	NULL
HIV	NULL
enhancer	NULL
binding	NULL
and	NULL
induction	NULL
,	NULL
factors	NULL
that	NULL
would	NULL
interact	NULL
functionally	NULL
with	NULL
other	NULL
sequences	NULL
in	NULL
the	NULL
LTR	NULL
.	NULL

This	NULL
is	NULL
unlikely	NULL
,	NULL
however	NULL
,	NULL
because	NULL
similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
a	NULL
TK-Luc	NULL
vector	NULL
driven	NULL
by	NULL
the	NULL
synthetic	NULL
oligonucleotide	NULL
sequence	NULL
of	NULL
the	NULL
HIV	NULL
enhancer	NULL
was	NULL
used	NULL
instead	NULL
of	NULL
the	NULL
HIV-LTR-Luc	NULL
constructions	NULL
.	NULL

The	NULL
second	NULL
possibility	NULL
would	NULL
be	NULL
that	NULL
the	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
induced	NULL
by	NULL
PMA	NULL
or	NULL
the	NULL
two	NULL
other	NULL
inducers	NULL
used	NULL
bind	NULL
to	NULL
the	NULL
HIV	NULL
enhancer	NULL
but	NULL
differ	NULL
qualitatively	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
HIV	NULL
enhancer	NULL
is	NULL
able	NULL
to	NULL
bind	NULL
purified	NULL
NF-	NULL
«	NULL
B	NULL
protein	NULL
(	NULL
26	NULL
)	NULL
but	NULL
also	NULL
protein	NULL
factors	NULL
with	NULL
a	NULL
different	NULL
molecular	NULL
weight	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
.	NULL

In	NULL
our	NULL
band-shift	NULL
assays	NULL
,	NULL
however	NULL
,	NULL
the	NULL
protein	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
induced	NULL
by	NULL
anti-CD3	NULL
antibody	NULL
or	NULL
rNF	NULL
behaved	NULL
indistinguishably	NULL
from	NULL
HEBP	NULL
induced	NULL
by	NULL
PMA	NULL
or	NULL
bona	NULL
fide	NULL
NF-	NULL
«	NULL
B	NULL
obtained	NULL
from	NULL
PMA-induced	NULL
70Z/3	NULL
cells	NULL
(	NULL
13	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Such	NULL
properties	NULL
are	NULL
compatible	NULL
with	NULL
the	NULL
interpretation	NULL
that	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
protein	NULL
complex	NULL
(	NULL
29	NULL
)	NULL
was	NULL
the	NULL
enhancer-binding	NULL
factor	NULL
detected	NULL
in	NULL
our	NULL
cell	NULL
system	NULL
,	NULL
whatever	NULL
the	NULL
inducer	NULL
used	NULL
.	NULL

If	NULL
this	NULL
interpretation	NULL
is	NULL
correct	NULL
,	NULL
we	NULL
are	NULL
bound	NULL
to	NULL
conclude	NULL
that	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
in	NULL
the	NULL
nucleus	NULL
is	NULL
not	NULL
a	NULL
sufficient	NULL
condition	NULL
for	NULL
the	NULL
HIV	NULL
enhancer	NULL
to	NULL
be	NULL
transactivated	NULL
in	NULL
nontumoral	NULL
T	NULL
lymphocytes	NULL
,	NULL
such	NULL
as	NULL
T-cell	NULL
clones	NULL
.	NULL

In	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
events	NULL
linked	NULL
to	NULL
cell	NULL
activation	NULL
appear	NULL
to	NULL
be	NULL
necessary	NULL
,	NULL
in	NULL
addition	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
translocation	NULL
,	NULL
to	NULL
induce	NULL
functional	NULL
interactions	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
protein	NULL
complex	NULL
with	NULL
the	NULL
HIV	NULL
enhancer	NULL
.	NULL

This	NULL
could	NULL
occur	NULL
through	NULL
either	NULL
induction	NULL
of	NULL
another	NULL
factor	NULL
undetectable	NULL
in	NULL
band-shift	NULL
assays	NULL
,	NULL
which	NULL
would	NULL
act	NULL
in	NULL
combination	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
or	NULL
,	NULL
more	NULL
probably	NULL
,	NULL
through	NULL
post-translational	NULL
modifications	NULL
of	NULL
one	NULL
or	NULL
more	NULL
protein	NULL
components	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Such	NULL
dissociation	NULL
between	NULL
DNA-protein	NULL
interaction	NULL
and	NULL
functional	NULL
induction	NULL
is	NULL
not	NULL
unprecedented	NULL
,	NULL
as	NULL
shown	NULL
with	NULL
the	NULL
c-fos	NULL
promoter	NULL
(	NULL
30	NULL
)	NULL
.	NULL

We	NULL
observed	NULL
that	NULL
NF-KB	NULL
induction	NULL
,	NULL
presumably	NULL
resulting	NULL
from	NULL
TCR-CD3-induced	NULL
protein	NULL
kinase	NULL
C	NULL
activation	NULL
,	NULL
was	NULL
not	NULL
sufficient	NULL
to	NULL
induce	NULL
LTR	NULL
transactivation	NULL
whereas	NULL
antigen	NULL
recognition	NULL
,	NULL
known	NULL
to	NULL
involve	NULL
costimulatory	NULL
signals	NULL
,	NULL
resulted	NULL
in	NULL
HIV	NULL
LTR	NULL
induction	NULL
.	NULL

It	NULL
appears	NULL
that	NULL
several	NULL
activation	NULL
signals	NULL
,	NULL
such	NULL
as	NULL
those	NULL
provided	NULL
by	NULL
antigen-presenting	NULL
cells	NULL
,	NULL
must	NULL
synergize	NULL
to	NULL
attain	NULL
both	NULL
full	NULL
T-cell	NULL
activation	NULL
and	NULL
HIV	NULL
LTR	NULL
transactivation	NULL
.	NULL

In	NULL
IL-2-dependent	NULL
cloned	NULL
T	NULL
lymphocytes	NULL
,	NULL
such	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
would	NULL
be	NULL
inducible	NULL
by	NULL
PMA	NULL
and	NULL
antigen	NULL
recognition	NULL
,	NULL
but	NULL
not	NULL
by	NULL
TNF	NULL
and	NULL
soluble	NULL
antibody	NULL
to	NULL
CD3	NULL
.	NULL

Stimulation	NULL
by	NULL
appropriate	NULL
ligands	NULL
of	NULL
single	NULL
transmembrane	NULL
receptors	NULL
,	NULL
such	NULL
as	NULL
the	NULL
CD3	NULL
complex	NULL
or	NULL
the	NULL
TNF	NULL
receptor	NULL
is	NULL
sufficient	NULL
for	NULL
induction	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
translocation	NULL
but	NULL
not	NULL
for	NULL
induction	NULL
of	NULL
HIV	NULL
LTR-dependent	NULL
transcription	NULL
.	NULL

These	NULL
observations	NULL
limit	NULL
the	NULL
hypothesis	NULL
that	NULL
exogenous	NULL
or	NULL
autocrine	NULL
secretion	NULL
of	NULL
TNF	NULL
alone	NULL
has	NULL
a	NULL
major	NULL
role	NULL
per	NULL
se	NULL
in	NULL
HIV	NULL
provirus	NULL
activation	NULL
,	NULL
although	NULL
it	NULL
may	NULL
amplify	NULL
it	NULL
.	NULL

Specific	NULL
antigen	NULL
recognition	NULL
through	NULL
the	NULL
TCR-CD3	NULL
complex	NULL
,	NULL
in	NULL
association	NULL
with	NULL
other	NULL
membrane	NULL
molecules	NULL
and	NULL
secondary	NULL
secretion	NULL
of	NULL
cytokines	NULL
,	NULL
is	NULL
the	NULL
physiological	NULL
signaling	NULL
system	NULL
inducing	NULL
full	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
their	NULL
basal	NULL
resting	NULL
state	NULL
and	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
the	NULL
main	NULL
trigger	NULL
of	NULL
HIV	NULL
transcription	NULL
in	NULL
infected	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
87	NULL
(	NULL
1990	NULL
)	NULL
7865	NULL
We	NULL
are	NULL
grateful	NULL
to	NULL
A.	NULL
Israel	NULL
and	NULL
S.	NULL
Michelson	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
and	NULL
to	NULL
M.	NULL
Policard	NULL
for	NULL
providing	NULL
blood	NULL
from	NULL
normal	NULL
donors	NULL
.	NULL

The	NULL
support	NULL
of	NULL
Agence	NULL
Nationale	NULL
de	NULL
Recherche	NULL
sur	NULL
le	NULL
SIDA	NULL
is	NULL
gratefully	NULL
acknowledged	NULL
.	NULL

U.	NULL
H.	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
fellowship	NULL
from	NULL
Comite	NULL
National	NULL
d'Action	NULL
contre	NULL
le	NULL
SIDA	NULL
,	NULL
F.B	NULL
.	NULL

was	NULL
supported	NULL
by	NULL
Agence	NULL
Nationale	NULL
de	NULL
Recherche	NULL
sur	NULL
le	NULL
SIDA	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
was	NULL
supported	NULL
by	NULL
Fondo	NULL
de	NULL
Investigaciones	NULL
Sanitarias	NULL
de	NULL
la	NULL
Seguridad	NULL
Social	NULL
(	NULL
Spain	NULL
)	NULL
and	NULL
Caja	NULL
de	NULL
Ahorros	NULL
y	NULL
Monte	NULL
de	NULL
Piedad	NULL
de	NULL
Madrid	NULL
.	NULL

DNAX	NULL
Research	NULL
Institute	NULL
is	NULL
supported	NULL
by	NULL
Schering-Plough	NULL
.	NULL

1	NULL
.	NULL

-	NULL
Schnittman	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Psallidopoulos	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Lane	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
Thomp-son	NULL
,	NULL
L.	NULL
,	NULL
Baseler	NULL
,	NULL
M.	NULL
,	NULL
Massari	NULL
,	NULL
F.	NULL
,	NULL
Fox	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
Saalzman	NULL
,	NULL
N.	NULL
P.	NULL
&	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
245	NULL
,	NULL
305-308	NULL
.	NULL

2	NULL
.	NULL

McElrath	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Pruett	NULL
,	NULL
J.	NULL
E.	NULL
&	NULL
Cohn	NULL
,	NULL
Z	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
675-679	NULL
.	NULL

Virelizier	NULL
,	NULL
J.-L.	NULL
(	NULL
1990	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

2	NULL
,	NULL
409-413	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
227-229	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1987	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
326	NULL
,	NULL
711-	NULL
713	NULL
.	NULL

6	NULL
.	NULL

Osborn	NULL
,	NULL
L.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
&	NULL
Nabel	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
2336-2340	NULL
.	NULL

7	NULL
.	NULL

Duh	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Maury	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Folks	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
&	NULL
Rabson	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
5974-5978	NULL
.	NULL

8	NULL
.	NULL

Israél	NULL
,	NULL
N.	NULL
,	NULL
Hazan	NULL
,	NULL
U.	NULL
,	NULL
Alcami	NULL
,	NULL
J.	NULL
,	NULL
Munier	NULL
,	NULL
A.	NULL
,	NULL
Arenzana-Seisdedos	NULL
,	NULL
F.	NULL
,	NULL
Bachelerie	NULL
,	NULL
F.	NULL
,	NULL
Israél	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Virelizier	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

143	NULL
,	NULL
3956-3960	NULL
.	NULL

9	NULL
.	NULL

Scheurich	NULL
,	NULL
P.	NULL
B.	NULL
,	NULL
Thoma	NULL
,	NULL
B.	NULL
,	NULL
Ucer	NULL
,	NULL
U	NULL
.	NULL

&	NULL
Pfizenmaier	NULL
,	NULL
K.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

138	NULL
,	NULL
1786-1790	NULL
.	NULL

10	NULL
.	NULL

Katz	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

1	NULL
,	NULL
213-219	NULL
.	NULL

11	NULL
.	NULL

-	NULL
Schmitt	NULL
,	NULL
C.	NULL
,	NULL
Ballet	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Agrapart	NULL
,	NULL
M.	NULL
&	NULL
Bizzini	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

12	NULL
,	NULL
849-854	NULL
.	NULL

12	NULL
.	NULL

Spits	NULL
,	NULL
H.	NULL
,	NULL
Yssel	NULL
,	NULL
H.	NULL
,	NULL
Terhost	NULL
,	NULL
C.	NULL
&	NULL
de	NULL
Vries	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1982	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

128	NULL
,	NULL
95-99	NULL
.	NULL

13	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
47	NULL
,	NULL
921-928	NULL
.	NULL

14	NULL
.	NULL

Arenzana-Seisdedos	NULL
,	NULL
F.	NULL
,	NULL
Mogensen	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Vuillier	NULL
,	NULL
F.	NULL
,	NULL
Fiers	NULL
,	NULL
W.	NULL
&	NULL
Virelizier	NULL
,	NULL
J.-L.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
6087-6091	NULL
.	NULL

15	NULL
.	NULL

Yssel	NULL
,	NULL
H.	NULL
,	NULL
de	NULL
Vries	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Koken	NULL
,	NULL
M.	NULL
,	NULL
Van	NULL
Blitterswijk	NULL
,	NULL
W.	NULL
&	NULL
Spits	NULL
,	NULL
H.	NULL
(	NULL
1984	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
72	NULL
,	NULL
219-227	NULL
.	NULL

16	NULL
.	NULL

Spits	NULL
,	NULL
H.	NULL
,	NULL
Keizer	NULL
,	NULL
G.	NULL
,	NULL
Borst	NULL
,	NULL
J.	NULL
,	NULL
Terhost	NULL
,	NULL
C.	NULL
,	NULL
Hekman	NULL
,	NULL
A	NULL
.	NULL

&	NULL
de	NULL
Vries	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1983	NULL
)	NULL
Hybridoma	NULL
2	NULL
,	NULL
423-428	NULL
.	NULL

17	NULL
.	NULL

Schwartz	NULL
,	NULL
O.	NULL
,	NULL
Virelizier	NULL
,	NULL
J.-L.	NULL
,	NULL
Montagnier	NULL
,	NULL
L.	NULL
&	NULL
Hazan	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Gene	NULL
88	NULL
,	NULL
197-205	NULL
.	NULL

18	NULL
.	NULL

Yano	NULL
,	NULL
O.	NULL
,	NULL
Kanellopoulos	NULL
,	NULL
J.	NULL
,	NULL
Kieran	NULL
,	NULL
M.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Israél	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Kourilsky	NULL
,	NULL
P.	NULL
(	NULL
1987	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

6	NULL
,	NULL
3317-3324	NULL
.	NULL

19	NULL
.	NULL

Deutsch	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Hoeffler	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Jameson	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Lin	NULL
,	NULL
J.	NULL
C.	NULL
&	NULL
Habener	NULL
,	NULL
J.	NULL
F.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263	NULL
,	NULL
18466-18472	NULL
.	NULL

20	NULL
.	NULL

Boshart	NULL
,	NULL
M.	NULL
,	NULL
Weber	NULL
,	NULL
F.	NULL
,	NULL
Jahn	NULL
,	NULL
G.	NULL
,	NULL
Dorsh-Hasler	NULL
,	NULL
K.	NULL
,	NULL
Fleck-enstein	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1985	NULL
)	NULL
Cell	NULL
41	NULL
,	NULL
521-530	NULL
.	NULL

21	NULL
.	NULL

Margolick	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Volkman	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Folks	NULL
,	NULL
T.	NULL
M.	NULL
&	NULL
Fauci	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

138	NULL
,	NULL
1719-1723	NULL
.	NULL

22	NULL
.	NULL

Horvat	NULL
,	NULL
R.	NULL
T.	NULL
&	NULL
Wood	NULL
,	NULL
C.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

132	NULL
,	NULL
2745-2751	NULL
.	NULL

23	NULL
.	NULL

Yssel	NULL
,	NULL
H.	NULL
,	NULL
Aubry	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
de	NULL
Waal	NULL
Malefijt	NULL
,	NULL
R.	NULL
,	NULL
de	NULL
Vries	NULL
,	NULL
J.	NULL
E.	NULL
&	NULL
Spits	NULL
,	NULL
H.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

139	NULL
,	NULL
2850-2855	NULL
.	NULL

24	NULL
.	NULL

Tong-Starksten	NULL
,	NULL
S.	NULL
,	NULL
Luciw	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Peterlin	NULL
,	NULL
B.	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

142	NULL
,	NULL
702-707	NULL
.	NULL

25	NULL
.	NULL

Mermod	NULL
,	NULL
N.	NULL
,	NULL
Williams	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

&	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
332	NULL
,	NULL
557-561	NULL
.	NULL

26	NULL
.	NULL

-	NULL
Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Kuang	NULL
,	NULL
A.	NULL
,	NULL
Gifford	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
8825-8829	NULL
.	NULL

27	NULL
.	NULL

Franza	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
Josephs	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
Gilman	NULL
,	NULL
M.	NULL
Z.	NULL
,	NULL
Ryan	NULL
,	NULL
W.	NULL
&	NULL
Clarkson	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
330	NULL
,	NULL
391-394	NULL
.	NULL

28	NULL
.	NULL

Isragl	NULL
,	NULL
A.	NULL
,	NULL
Le	NULL
Bail	NULL
,	NULL
O.	NULL
,	NULL
Hatat	NULL
,	NULL
D.	NULL
,	NULL
Piette	NULL
,	NULL
J..	NULL
Kieran	NULL
,	NULL
M.	NULL
,	NULL
Logeat	NULL
,	NULL
F.	NULL
,	NULL
Wallach	NULL
,	NULL
D.	NULL
,	NULL
Fellous	NULL
,	NULL
M.	NULL
&	NULL
Kourilsky	NULL
,	NULL
F.	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
3793-3800	NULL
.	NULL

29	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

3	NULL
,	NULL
1689-1698	NULL
.	NULL

30	NULL
.	NULL

Prywes	NULL
,	NULL
R.	NULL
&	NULL
Roeder	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
47	NULL
,	NULL
777-784.	NULL
ii	NULL
p	NULL
to	NULL

